GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (FRA:1HM) » Definitions » 3-Year FCF Growth Rate

Adaptive Biotechnologies (FRA:1HM) 3-Year FCF Growth Rate : 3.40% (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies 3-Year FCF Growth Rate?

Adaptive Biotechnologies's Free Cash Flow per Share for the three months ended in Jun. 2024 was €-0.12.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 3.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 7 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Adaptive Biotechnologies was 3.40% per year. The lowest was -70.80% per year. And the median was -53.80% per year.


Competitive Comparison of Adaptive Biotechnologies's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Adaptive Biotechnologies's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adaptive Biotechnologies's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's 3-Year FCF Growth Rate falls into.



Adaptive Biotechnologies 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Adaptive Biotechnologies  (FRA:1HM) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Adaptive Biotechnologies 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Adaptive Biotechnologies Business Description

Traded in Other Exchanges
Address
1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Adaptive Biotechnologies Headlines

No Headlines